Michael D. Pak

Array ( [id] => 10095896 [patent_doc_number] => 09132192 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-09-15 [patent_title] => 'Anti-EGFR antibodies and uses thereof' [patent_app_type] => utility [patent_app_number] => 13/925923 [patent_app_country] => US [patent_app_date] => 2013-06-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15583 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 70 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13925923 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9108238 [patent_doc_number] => 20130281370 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-10-24 [patent_title] => 'ANGIOGENESIS PROMOTED BY CAGED GROWTH FACTORS' [patent_app_type] => utility [patent_app_number] => 13/925612 [patent_app_country] => US [patent_app_date] => 2013-06-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6744 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13925612 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10283418 [patent_doc_number] => 20150168416 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-06-18 [patent_title] => 'KITS FOR DETECTING AND MONITORING ENDOCRINE DISRUPTING CHEMICALS (EDCs)' [patent_app_type] => utility [patent_app_number] => 14/405696 [patent_app_country] => US [patent_app_date] => 2013-06-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 22 [patent_no_of_words] => 21464 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14405696 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9197609 [patent_doc_number] => 20130336924 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-12-19 [patent_title] => 'Ligands Modified by Circular Permutation as Agonists and Antagonists' [patent_app_type] => utility [patent_app_number] => 13/911827 [patent_app_country] => US [patent_app_date] => 2013-06-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 19222 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13911827 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9197610 [patent_doc_number] => 20130336925 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-12-19 [patent_title] => 'Fusion Polypeptides Comprising Mucin-Domain Polypeptide Linkers' [patent_app_type] => utility [patent_app_number] => 13/911834 [patent_app_country] => US [patent_app_date] => 2013-06-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 19730 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13911834 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9995655 [patent_doc_number] => 09040248 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-05-26 [patent_title] => 'Kits for detecting and monitoring endocrine disrupting chemicals (EDCs)' [patent_app_type] => utility [patent_app_number] => 13/912071 [patent_app_country] => US [patent_app_date] => 2013-06-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 38 [patent_no_of_words] => 19348 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 154 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13912071 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15057389 [patent_doc_number] => 10458993 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-10-29 [patent_title] => Assay for assessing conformational stability of membrane protein [patent_app_type] => utility [patent_app_number] => 14/404768 [patent_app_country] => US [patent_app_date] => 2013-05-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 11970 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 109 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14404768 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9147824 [patent_doc_number] => 20130302347 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-11-14 [patent_title] => 'NOVEL RECEPTOR-LIGAND INTERACTION AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 13/900707 [patent_app_country] => US [patent_app_date] => 2013-05-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 32 [patent_figures_cnt] => 32 [patent_no_of_words] => 19600 [patent_no_of_claims] => 64 [patent_no_of_ind_claims] => 44 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13900707 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11178957 [patent_doc_number] => 09410945 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-08-09 [patent_title] => 'Brown adipocyte progenitors in human skeletal muscle' [patent_app_type] => utility [patent_app_number] => 13/875711 [patent_app_country] => US [patent_app_date] => 2013-05-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 16 [patent_no_of_words] => 11087 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 67 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13875711 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8976044 [patent_doc_number] => 20130209474 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-08-15 [patent_title] => 'WISE/SOST NUCLEIC ACID SEQUENCES AND AMINO ACID SEQUENCES' [patent_app_type] => utility [patent_app_number] => 13/863939 [patent_app_country] => US [patent_app_date] => 2013-04-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 21 [patent_no_of_words] => 36682 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13863939 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10142290 [patent_doc_number] => 09175089 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-11-03 [patent_title] => 'Anti-LGR5 antibodies and immunoconjugates' [patent_app_type] => utility [patent_app_number] => 13/853620 [patent_app_country] => US [patent_app_date] => 2013-03-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 36 [patent_figures_cnt] => 37 [patent_no_of_words] => 56012 [patent_no_of_claims] => 31 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 163 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13853620 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11923872 [patent_doc_number] => 09791448 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-10-17 [patent_title] => 'Breast cancer assay' [patent_app_type] => utility [patent_app_number] => 14/389108 [patent_app_country] => US [patent_app_date] => 2013-03-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 11445 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 114 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14389108 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9857334 [patent_doc_number] => 20150037351 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-02-05 [patent_title] => 'NOVEL THERAPEUTIC TARGET FOR THE PREVENTION OF TUMOUR METASTASIS' [patent_app_type] => utility [patent_app_number] => 14/386502 [patent_app_country] => US [patent_app_date] => 2013-03-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 19551 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14386502 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11243654 [patent_doc_number] => 09469686 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-10-18 [patent_title] => 'Anti-GP73 monoclonal antibodies and methods of obtaining the same' [patent_app_type] => utility [patent_app_number] => 13/836229 [patent_app_country] => US [patent_app_date] => 2013-03-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 21 [patent_no_of_words] => 66584 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 102 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13836229 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9735877 [patent_doc_number] => 20140271589 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-09-18 [patent_title] => 'TREATMENT OF COLLAGEN DEFECTS USING PROTEIN SOLUTIONS' [patent_app_type] => utility [patent_app_number] => 13/840129 [patent_app_country] => US [patent_app_date] => 2013-03-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 19263 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13840129 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11635146 [patent_doc_number] => 09657105 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-05-23 [patent_title] => 'CD123-specific chimeric antigen receptor redirected T cells and methods of their use' [patent_app_type] => utility [patent_app_number] => 13/844048 [patent_app_country] => US [patent_app_date] => 2013-03-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 18 [patent_no_of_words] => 13801 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 68 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13844048 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10548527 [patent_doc_number] => 09273138 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-03-01 [patent_title] => 'Humanized forms of monoclonal antibodies to human GnRH receptor' [patent_app_type] => utility [patent_app_number] => 13/797653 [patent_app_country] => US [patent_app_date] => 2013-03-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 7 [patent_no_of_words] => 2389 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 322 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13797653 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9081050 [patent_doc_number] => 20130266579 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-10-10 [patent_title] => 'Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof' [patent_app_type] => utility [patent_app_number] => 13/815553 [patent_app_country] => US [patent_app_date] => 2013-03-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 151303 [patent_no_of_claims] => 75 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13815553 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9081050 [patent_doc_number] => 20130266579 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-10-10 [patent_title] => 'Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof' [patent_app_type] => utility [patent_app_number] => 13/815553 [patent_app_country] => US [patent_app_date] => 2013-03-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 151303 [patent_no_of_claims] => 75 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13815553 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9369832 [patent_doc_number] => 20140079706 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-03-20 [patent_title] => 'COMBINATION THERAPY OF ANTIBODIES AGAINST HUMAN CSF-1R AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 13/789373 [patent_app_country] => US [patent_app_date] => 2013-03-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 51403 [patent_no_of_claims] => 37 [patent_no_of_ind_claims] => 9 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13789373 [rel_patent_id] =>[rel_patent_doc_number] =>)